干细胞领域知识发现平台

提升科研信息化水平
支撑研究所科技创新

  融合多源信息    打通数据孤岛
  挖掘知识关联    放大数据价值
  集成知识计算    促进知识发现

知识棱镜

共找到256条结果
排序:


Abstract

The present invention addresses the problem of providing: a trophic factor release agent which makes it possible to increase the quantity of a trophic factor released from cells in a cell transplantation therapy or the like; and an inflammatory disease treatment agent. According to the present invention, a trophic factor release agent is provided, which comprises a cell structure comprising biocompatible polymer blocks and cells, wherein multiple biocompatible polymer blocks are arranged in gaps formed between multiple cells, the size of each of the biocompatible polymer blocks is 20 to 200 μm inclusive and the trophic factor is released from the cells.

公开时间: 2017-10-26
发明人:Zhao Yi, Mcmillan Michael, Higuchi Yusuke, Kahn Michael, Nguyen Cu D
知识棱镜:

Abstract

Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 is hydrogen or C1-C6 alkyl; ring A is cyclohexyl or phenyl, optionally substituted; ring B is aryl or a nitrogen-containing heteroaryl, optionally substituted; ring C is phenyl substituted with hydroxyl; each L1, L2 and L3 is independently C1-C6 alkyl, -CONR2- or -CONR2-X-C1-C6 alkyl-, each optionally substituted; R2 is hydrogen or C1-C6 alkyl; and X is a bond or a 5-6 membered heterocycle containing up to 3 ring heteroatoms; and methods of use such as a method for increasing hematopoiesis, for enhancing expansion of a hematopoietic stem cell (HSC), or for inhibiting an interaction between a β-, and/or γ-catenin protein and a p-300 protein in a cell or a subject by administering a compound of Formula (I) to the subject.


Abstract

Methods are disclosed for forming bone and/or cartilage in an avian subject. The methods include administering to the avian subject a therapeutically effective amount of a composition comprising avian mesenchymal stem cells and a hydrogel that supports the differentiation of the avian mesenchymal stem cells into cells of an osteogenic and/or condrogenic lineage. In some embodiments, methods are disclosed for repairing a bone defect and preventing infection, such as that associated bone fracture, in an avian subject. The methods include administering locally to the bone defect a composition comprising a therapeutically effective amount of avian mesenchymal stem cells and a hydrogel, such as a methacrylated gelatin hydrogel.


Abstract

The present invention relates to a method for preparing an induced dopaminergic neuronal progenitor (iDP), and a cell therapeutic agent and a composition for treating or preventing Parkinson's disease, containing the iDP prepared thereby as an active ingredient, the method comprising the steps of: inducing Oct4, Sox2, Klf4 and c-Myc gene expression in adult cells; and directly reprogramming the adult cells into iDPs by treating the cells with sonic hedgehog (SHH) and fibroblast growth factor 8 (FGF8).In addition, the present invention relates to a method for preparing mesencephalic dopaminergic neurons, comprising the steps of: isolating a neural stem cell-like colony (NSC-like colony) by culturing the iDP; and making the isolated colony be a single cell, and culturing the same in a neuronal differentiation medium. Additionally, the present invention relates to a method for treating Parkinson's disease or a method for screening an agent for preventing or treating Parkinson's disease, by using the cell of the present invention. An iDP prepared by the method for preparing an iDP of the present invention has remarkably high efficiency for differentiating into dopaminergic neurons compared with known methods, and since the somatic cells of a patient can be used, there are no side effects such as immunogenicity and no ethical problems, thereby enabling the iDP to be widely used in the relevant fields.


Abstract

Methods for the efficient isolation and use of pluripotent adipose-derived stem cells (PASCs) are provided. In certain embodiments the methods involve providing an adipose tissue sample from which the stromal vascular fraction is co-cultured with the adipocyte fraction. PASCs can be isolated with a high degree of purification without requiring an additional cell enrichment process (e.g. cell sorting). PASCs and their conditioned media can be used for tissue regeneration within hours of harvesting the adipose tissue, and without requiring cell expansion. PASCs can grow as floating individual cells, as clusters of cells, or attached to surface(s) of the culture vessel. PASCs do not produce teratomas in vivo, nor do they induce immunorejection upon transplantation, and they achieve a high efficiency in grafting. The cells and compositions can be used for cell therapy and to screen new drugs.


Abstract

The present invention determined that EGFL6 functions as a tumor vascular regulator of ovarian cancer stem cells (CSC). In addition, the present invention determined that a novel EGFL6 blocking antibody was able to restrict cancer cell growth and delay disease recurrence. As such, the present invention provides compositions and methods for inhibiting cancer cell growth, proliferation and/or metastasis. In particular, the present invention provides methods for inhibiting cancer cell growth, proliferation and/or metastasis through administration of a composition comprising an agent capable of inhibiting the function of EGFL6 (e.g., thereby inhibiting related cancer cell growth). In some embodiments, the agent capable of inhibiting the function of EGFL6 is an EGFL6 blocking antibody. The agents and related compositions additionally find use in diagnostic and research settings

公开时间: 2014-09-04
发明人:Levesque Jean-pierre Jose Rene, Winkler Ingrid Gabriele
知识棱镜:

Abstract

Disclosed is the use of a HIF-α potentiating agent and a mobilizer of hematopoietic stem cells and/or progenitor cells in methods and compositions for mobilizing hematopoietic stem cell and progenitor cells from the bone marrow into the peripheral blood. The compositions and methods are particularly useful for stem cell transplantation and for treating or preventing immune deficiencies.

公开时间: 2014-07-03
发明人:Cheve Gwénaël, Dayde-cazals Bénédicte, Fauvel Bénédicte, Bories Cédric, Yasri Abdelaziz
知识棱镜:

Abstract

The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the present invention thus also includes the preparation of compounds of formula (I), their uses, in particular in the inhibition of protein kinases which are implicated for example in numerous diseases such as cancers or immune system disorders.

公开时间: 2014-06-12
发明人:Andersch Wolfram, Springer Bernd, Thielert Wolfgang, Lüth Peter, Eiben Ute
知识棱镜:

Abstract

The present invention relates to a composition comprising at least one biological control agent selected from the group consisting of Paecilomyces lilacinus strain 251 (AGAL No. 89/030550) and Coniothyrium minitans CON/M/91 -08 (DSM 9660) and/or a mutant of these strains having all the identifying characteristics of the respective strain, and/or at least one metabolite produced by the respective strain that exhibits activity against nematodes, insects and/or phytopathogens, and at least and at least one further biological control agent (II) which is selected from the group consisting of fungi and yeasts in a synergistically effective amount. Furthermore, the present invention relates to a kit of parts comprising said composition and the use of said composition.


Abstract

Methods for preparing a composition containing extracts of activated amphibian oocytes, the method where the composition is a pharmaceutical composition comprising an equal volume of the extra-oocyte composition and the intra-oocyte composition, and a method for treating a disease, disorder, condition or injury characterized by a damaged or a cancerous differentiated cell including: (a) preparing the composition by the described method; (b) formulating a pharmaceutical composition comprising an equal volume of the extra-oocyte composition and the intra-oocyte composition, and optionally a carrier; and { c) administering a therapeutic amount of the pharmaceutical composition of (b) to a subject in need thereof, where the therapeutic amount as effective to reprogram the damaged or cancerous cells into iPSC-like cells capable of differentiating into cells capable of repairing the damaged or cancerous cells, thereby treating the disease, disorder, injury or condition.

国别地区

发明人

国际专利分类号